Cargando…
Long-Term Exposure and Safety of a Novel Topical Rapamycin Cream for the Treatment of Facial Angiofibromas in Tuberous Sclerosis Complex: Results From a Single-Center, Open-Label Trial
Facial angiofibromas, composed of fibrous tissue and blood vessels appearing on the face, are closely associated with tuberous sclerosis complex. Historically, oral rapamycin, a mammalian target of the rapamycin inhibitor of cell proliferation, has been used to treat visceral tuberous sclerosis–rela...
Autores principales: | Wheless, Margaret C., Takwi, Apana A., Almoazen, Hassan, Wheless, James W. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6589944/ https://www.ncbi.nlm.nih.gov/pubmed/31259191 http://dx.doi.org/10.1177/2329048X19835047 |
Ejemplares similares
-
Topical rapamycin for facial angiofibromas in tuberous sclerosis complex
por: Safa, Gilles
Publicado: (2017) -
Topical rapamycin (sirolimus) for facial angiofibromas
por: Madke, Bhushan
Publicado: (2013) -
Facial Angiofibromas of Tuberous Sclerosis Treated with Topical Sirolimus in an Indian Patient
por: Vasani, Resham J
Publicado: (2015) -
Facial Angiofibromas and Periungual Fibromas in Tuberous Sclerosis
por: Tsujimoto, Hiraku, et al.
Publicado: (2017) -
Topical Rapamycin for Facial Angiofibromas in a Child with Tuberous Sclerosis Complex (TSC): A Case Report and Long-Term Follow-up
por: Ebrahimi-Fakhari, Daniel, et al.
Publicado: (2017)